PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 13, 2024Journal of Cystic Fibrosis34 citationsOpen Access

Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies

View Full Paper
AKAleksandra KowalikEREmma RobertsAHAnna Hedborg Harris

Key Points

Key points are not available for this paper at this time.

Abstract

•Exposure to ETI in utero might prevent organ damage in fetus with CF.•Normal vas deferens found in a baby boy with CF exposed to ETI in utero.•Normal pancreatic function in two infants with CF exposed to ETI in utero.•Gallstones in an infant with CF exposed to ETI in utero but not after birth.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kowalik et al. (2024) studied this question.

synapsesocial.com/papers/68e64d72b6db6435875de22chttps://doi.org/10.1016/j.jcf.2024.06.003
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gallbladder and bile duct disease in Cystic Fibrosis2017 · 70 citations
  2. 2Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor2021 · 43 citations
  3. 3Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy2021 · 117 citations
  4. 4Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation2021 · 116 citations
  5. 5A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus2022 · 107 citations